Overview
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
Status:
Recruiting
Recruiting
Trial end date:
2026-01-16
2026-01-16
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Janssen Research & Development, LLC
Criteria
Inclusion Criteria:- Signed informed consent form 18 years of age or older
- Documented diagnosis of ulcerative colitis (UC) of at least 12 weeks prior to
screening
- Moderately to severely active UC as per the modified Mayo score
- Demonstrated inadequate response to or intolerance of conventional therapy and/or
advanced therapy as defined in the protocol
Exclusion Criteria:
- Participants with current or prior diagnosis of fulminant colitis and/or toxic
megacolon
- UC limited to rectum only or to less than (<) 15 centimeters (cm) of colon
- Presence of a stoma
- Presence or history of fistula
- History of extensive colonic resection (example, <30 cm of colon remaining)
- Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's
colitis or clinical findings suggestive of Crohn's disease